[New Developments in the Antiarrhythmic Therapy of Atrial Fibrillation]

Overview

Journal Herzschrittmacherther Elektrophysiol

Date 2010 Nov 26

PMID 21107985

Authors

H Simon

K Simon Demel

G Ritscher

O Turschner

J Brachmann

Affiliations

Soon will be listed here.

Abstract

Atrial fibrillation, which is associated with a worsening of congestive heart failure symptoms, an increased rate of stoke, and increased mortality, is still difficult to treat. New therapies must not only increase effectiveness, but also have to have an improved safety profile, in order to avoid sodium channel block in the ventricle of older patients with atrial fibrillation, and also prevent electrical and morphological remodeling. Dronedarone is less effective compared to amiodarone, but has a better side effect profile which leads to fewer discontinuations of treatment. The atrial ion channels are specifically blocked by a number of prospective antiarrhythmic substances. The most advanced is the testing of vernakalant (RSD1235), which primarily suppresses the I(Kur) current. Ranolazine is a new antianginal substance which influences the atrial ion channels and leads to a significant reduction of atrial and more specifically ventricular tachyarrhythmias. A number of other drugs are in development. They will lead to a better understanding of which form of atrial fibrillation can be best treated with which antiarrhythmic agent.

References

Calo L, Bianconi L, Colivicchi F, Lamberti F, Loricchio M, De Ruvo E . N-3 Fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a randomized, controlled trial. J Am Coll Cardiol. 2005; 45(10):1723-8. DOI: 10.1016/j.jacc.2005.02.079. View

Morrow J, Cannon C, Reiffel J . New antiarrhythmic drugs for establishing sinus rhythm in atrial fibrillation: what are our therapies likely to be by 2010 and beyond?. Am Heart J. 2007; 154(5):824-9. DOI: 10.1016/j.ahj.2007.06.041. View

Peterman C, Sanoski C . Tecadenoson: a novel, selective A1 adenosine receptor agonist. Cardiol Rev. 2005; 13(6):315-21. DOI: 10.1097/01.crd.0000181621.84565.9d. View

Mozaffarian D, Psaty B, Rimm E, Lemaitre R, Burke G, Lyles M . Fish intake and risk of incident atrial fibrillation. Circulation. 2004; 110(4):368-73. PMC: 1201400. DOI: 10.1161/01.CIR.0000138154.00779.A5. View

Ehrlich J, Hohnloser S, Nattel S . Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence. Eur Heart J. 2005; 27(5):512-8. DOI: 10.1093/eurheartj/ehi668. View

Gautier P, Serre M, Cosnier-Pucheu S, Djandjighian L, Roccon A, Herbert J . In vivo and in vitro antiarrhythmic effects of SSR149744C in animal models of atrial fibrillation and ventricular arrhythmias. J Cardiovasc Pharmacol. 2005; 45(2):125-35. DOI: 10.1097/01.fjc.0000151899.03379.76. View

Burashnikov A, Di Diego J, Zygmunt A, Belardinelli L, Antzelevitch C . Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine. Circulation. 2007; 116(13):1449-57. PMC: 2566303. DOI: 10.1161/CIRCULATIONAHA.107.704890. View

Echt D, Liebson P, Mitchell L, Peters R, BARKER A, Arensberg D . Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med. 1991; 324(12):781-8. DOI: 10.1056/NEJM199103213241201. View

Ozaydin M, Peker O, Erdogan D, Kapan S, Turker Y, Varol E . N-acetylcysteine for the prevention of postoperative atrial fibrillation: a prospective, randomized, placebo-controlled pilot study. Eur Heart J. 2008; 29(5):625-31. DOI: 10.1093/eurheartj/ehn011. View

10.

Patti G, Chello M, Candura D, Pasceri V, DAmbrosio A, Covino E . Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study. Circulation. 2006; 114(14):1455-61. DOI: 10.1161/CIRCULATIONAHA.106.621763. View

11.

Piccini J, Hasselblad V, Peterson E, Washam J, Califf R, Kong D . Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation. J Am Coll Cardiol. 2009; 54(12):1089-95. DOI: 10.1016/j.jacc.2009.04.085. View

12.

Kaufman E, Waldo A . The impact of asymptomatic atrial fibrillation. J Am Coll Cardiol. 2004; 43(1):53-4. DOI: 10.1016/j.jacc.2003.10.013. View

13.

Bode F, KATCHMAN A, Woosley R, Franz M . Gadolinium decreases stretch-induced vulnerability to atrial fibrillation. Circulation. 2000; 101(18):2200-5. DOI: 10.1161/01.cir.101.18.2200. View

14.

Lee K, Everett 4th T, Rahmutula D, Guerra J, Wilson E, Ding C . Pirfenidone prevents the development of a vulnerable substrate for atrial fibrillation in a canine model of heart failure. Circulation. 2006; 114(16):1703-12. PMC: 2129103. DOI: 10.1161/CIRCULATIONAHA.106.624320. View

15.

Le Heuzey J, De Ferrari G, Radzik D, Santini M, Zhu J, Davy J . A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. J Cardiovasc Electrophysiol. 2010; 21(6):597-605. DOI: 10.1111/j.1540-8167.2010.01764.x. View

16.

Davy J, Herold M, Hoglund C, Timmermans A, Alings A, Radzik D . Dronedarone for the control of ventricular rate in permanent atrial fibrillation: the Efficacy and safety of dRonedArone for the cOntrol of ventricular rate during atrial fibrillation (ERATO) study. Am Heart J. 2008; 156(3):527.e1-9. DOI: 10.1016/j.ahj.2008.06.010. View

17.

Roy D, Pratt C, Torp-Pedersen C, Wyse D, Toft E, Juul-Moller S . Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial. Circulation. 2008; 117(12):1518-25. DOI: 10.1161/CIRCULATIONAHA.107.723866. View

18.

Kober L, Torp-Pedersen C, McMurray J, Gotzsche O, Levy S, Crijns H . Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med. 2008; 358(25):2678-87. DOI: 10.1056/NEJMoa0800456. View

19.

Rossman E, Liu K, Morgan G, Swillo R, Krueger J, Gardell S . The gap junction modifier, GAP-134 [(2S,4R)-1-(2-aminoacetyl)-4-benzamido-pyrrolidine-2-carboxylic acid], improves conduction and reduces atrial fibrillation/flutter in the canine sterile pericarditis model. J Pharmacol Exp Ther. 2009; 329(3):1127-33. DOI: 10.1124/jpet.108.150102. View

20.

Waldo A, Camm A, deRuyter H, Friedman P, MacNeil D, Pauls J . Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol. Lancet. 1996; 348(9019):7-12. DOI: 10.1016/s0140-6736(96)02149-6. View